Briefing

Featured article

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Also in this section

News in Numbers

Latest News

Latest Deals

03/31/2025 16:22:49
  • Home | Are European biopharma manufacturers ‘nearshoring’?
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • MilliporeSigma
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Datwyler Company Insight
  • Datwyler
  • Frewitt Company Insight
  • In Depth
  • Are European biopharma manufacturers ‘nearshoring’?
  • Inborn errors of metabolism elicit unique challenges for therapy development
  • GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
  • European agencies catch up with speedier regulatory pathways for CGTs in the US
  • USAID funding fallout: sponsors, and agencies may have to fill funding gap
  • Pfizer’s bet on gene therapies in haemophilia has been a bust
  • Simtra
  • Zenatek Company Insight
  • Listings
  • Events
  • Excellence Awards
  • Buyer's Guides
  • Next issue
03/31/2025 00:00:00